Shire shares fall 13% as rival drug gets US approval

Shire Plc

Last Updated at 01 Sep 2014, 11:36 ET *Chart shows local time Shire Plc intraday chart
price change %
4864.00 p -

Related Stories

Shares in pharmaceutical company Shire fell almost 13% after US regulators approved a rival's cut-price version of its drug Adderall XR.

The US Food and Drug Administration had approved Actavis Group's generic version of Shire's hyperactivity disorder drug on Saturday.

Despite the news, Shire said it would deliver good full-year earnings growth.

Shire's shares fell 12.7% in early trading, making it the biggest faller on the FTSE 100.

Adderall XR is Shire's second-biggest selling drug. Until now, Shire has been the sole producer of the two forms of Adderall XR, and analysts said the arrival of a new competitor would increase pricing pressure.

Deutsche Bank cut its 2012-2013 earnings forecast by 5-6% to reflect the new competition, but said it still expected double-digit growth from the drugmaker.

Shire said that it would remain competitive in the Adderall XR marketplace, and "continues to believe that it will deliver good, full year 2012 earnings growth".

More on This Story

Related Stories

The BBC is not responsible for the content of external Internet sites

More Business stories



BBC © 2014 The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.